Related Experiment Video
Updated: Jun 5, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Adolescents and young adults with acute lymphoblastic leukemia
1University of Chicago, Medical Center, Chicago, IL 60637, USA. wstock@medicine.bsd.uchicago.edu
Insights
Adolescents and young adults with acute lymphoblastic leukemia (ALL) face unique treatment challenges. Research focuses on improving survival for this group through tailored clinical trials and biological insights.
Area of Science:
- Hematology
- Oncology
- Pediatric Oncology
- Adult Oncology
Background:
- Acute lymphoblastic leukemia (ALL) affects all age groups, with better survival rates in children than adults.
- Adolescents and young adults (AYAs) with ALL present unique therapeutic challenges, bridging pediatric and adult care.
- Current treatment disparities necessitate specialized approaches for AYAs with ALL.
Purpose of the Study:
- To review current controversies and recent advancements in treating adolescents and young adults with ALL.
- To highlight prospective clinical trials designed specifically for AYAs with ALL.
- To improve understanding of disease biology, prognostic factors, and treatment outcomes in AYAs with ALL.
Main Methods:
- Review of current literature and clinical trial data concerning ALL in adolescents and young adults.
- Analysis of disease biology, prognostic factors, and treatment outcomes.
- Focus on prospective clinical trials tailored for the AYA ALL population.
Main Results:
- Significant progress in pediatric ALL survival contrasts with suboptimal outcomes in adult ALL.
- Dedicated clinical trials for AYAs with ALL are yielding new clinical, psychosocial, and biological insights.
- The unique needs of AYAs with ALL are being addressed through specialized research initiatives.
Conclusions:
- Adolescents and young adults with ALL require distinct treatment strategies.
- Ongoing research and clinical trials are crucial for improving survival in AYAs with ALL.
- Further investigation into disease biology and psychosocial factors will enhance therapeutic outcomes.
Abstract:
During the last decade, increasing attention has been paid to a unique group of patients with acute lymphoblastic leukemia (ALL) who lie at the crossroad of therapeutic care by pediatric and adult hematologists/oncologists. ALL is a disease that affects infants, children, adolescents, and adult patients. With current therapies, the vast majority of children with ALL are now long-term survivors; unfortunately, the same good results have not yet been obtained for adults with ALL. This review will describe current controversies surrounding the treatment of adolescents and young adults with ALL--a group who finds themselves in the transition from "pediatric" to "adult" treatment approaches. The review focuses on recent insights into disease biology, prognostic factors, and treatment outcomes that have led to a series of prospective clinical trials specifically designed for adolescents and younger adults (AYAs) with ALL. These trials have been designed to provide important new clinical, psychosocial, and biological insights, and to further improve the survival of this challenging and unique group of patients.
Related Concept Videos
01:23Cells of the Adaptive Immune Response
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...